Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zirconium 89 DFO MSTP 2109A - Memorial Sloan Kettering Cancer Center

Drug Profile

Zirconium 89 DFO MSTP 2109A - Memorial Sloan Kettering Cancer Center

Alternative Names: 89Zr-DFO-MSTP2109A; Zirconium-89 DFO MSTP 2109A

Latest Information Update: 18 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Genentech; Memorial Sloan-Kettering Cancer Center
  • Class Antibody diagnostics; Drug conjugates; Immunoconjugates; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Prostate cancer

Most Recent Events

  • 02 May 2023 Memorial Sloan Kettering Cancer Center and Genentech complete a phase I/II trial for Prostate cancer (Diagnosis) in USA (NCT01774071)
  • 18 Feb 2016 Phase-I/II development is ongoing in USA
  • 18 Aug 2015 Memorial Sloan Kettering Cancer Center and Genentech complete enrolment in a phase I/II trial for Prostate cancer (Diagnosis) in USA (NCT01774071)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top